临床试验/IRCT20210519051345N65

IRCT20210519051345N65招募中Unknown

In vivo bioequivalence study of Indapamide 1.5 mg tablet manufactured by Pars Darou Co. compared with innovator product

Tabriz University of Medical Sciences0 个研究点目标入组 24 人开始时间: 待定最近更新: 2024年8月26日

适应症

试验速览

阶段: Unknown
状态: 招募中
发起方: Tabriz University of Medical Sciences
入组人数: 24

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 years 至 59 years（—）
性别: All

入选标准

•General Health (in terms of Liver, Heart and Kidney)
•Age between 18-59 years

排除标准

•History of cardiovascular disease, liver and kidney disease
•Alcohol and drug addiction
•History of drug allergy

研究者

发起方

Tabriz University of Medical Sciences

相似试验

Bioequivalence study of Indapamide 5.1 mg tabletThis study is performed on healthy volunteers..

IRCT20200105046010N84Darou darman Arang24

Bioequivalence study of Amantadine 100 mg capsuleIn the present study, no diseases will be examined and products will be administered by healthy volunteers.

IRCT20210519051345N7Tabriz University of Medical Sciences24

enalidomide cap. 25mg Sobhan Oncology (LENASOB® 25mg), In-Vivo Bioequivalence in iranian healthy volunteer.In this study, the disease is not examined. Subject bioequivalence test and reference tablets Teriflunomide studied..

IRCT20200105046010N26SOBHAN ONCOLOGY Pharmaceutical24

enalidomide tablet 25mg ABIDI (MYLODEQ® 25mg), In-Vivo Bioequivalence in iranian healthy volunteer, In-Vivo Bioequivalence in iranian healthy volunteerIn this study the bioequivalence of test and brand of Lenalidomide tablet will evaluated..

IRCT20200105046010N6Tabriz University of Medical Sciences24

In-vivo Bioequivalence Test of Linalidomide capsules with brand drug (REVLIMID® 25 mg, Celgene, Bristol-Myers Squibb, UK)

IRCT20200105046010N53Actero middle east Pharm. Co.24